AI Article Synopsis

  • SMPD1 gene variants, particularly p.L302P and p.fsP330, are associated with an increased risk of developing Parkinson's disease (PD) in certain populations, specifically the Ashkenazi Jewish cohort.
  • Analysis revealed that lower acid-sphingomyelinase activity in PD patients is linked to an earlier onset of the disease, indicating its potential role as a biomarker.
  • Experimental findings showed that SMPD1 mutations disrupt the normal function of acid-sphingomyelinase, leading to higher levels of α-synuclein in dopaminergic cells, which may contribute to the pathogenesis of PD.

Article Abstract

Background: SMPD1 (acid-sphingomyelinase) variants have been associated with Parkinson's disease in recent studies. The objective of this study was to further investigate the role of SMPD1 mutations in PD.

Methods: SMPD1 was sequenced in 3 cohorts (Israel Ashkenazi Jewish cohort, Montreal/Montpellier, and New York), including 1592 PD patients and 975 controls. Additional data were available for 10,709 Ashkenazi Jewish controls. Acid-sphingomyelinase activity was measured by a mass spectrometry-based assay in the New York cohort. α-Synuclein levels were measured in vitro following CRISPR/Cas9-mediated knockout and siRNA knockdown of SMPD1 in HeLa and BE(2)-M17 cells. Lysosomal localization of acid-sphingomyelinase with different mutations was studied, and in silico analysis of their effect on acid-sphingomyelinase structure was performed.

Results: SMPD1 mutations were associated with PD in the Ashkenazi Jewish cohort, as 1.4% of PD patients carried the p.L302P or p.fsP330 mutation, compared with 0.37% in 10,709 Ashkenazi Jewish controls (OR, 3.7; 95%CI, 1.6-8.2; P = 0.0025). In the Montreal/Montpellier cohort, the p.A487V variant was nominally associated with PD (1.5% versus 0.14%; P = 0.0065, not significant after correction for multiple comparisons). Among PD patients, reduced acid-sphingomyelinase activity was associated with a 3.5- to 5.8-year earlier onset of PD in the lowest quartile versus the highest quartile of acid-sphingomyelinase activity (P = 0.01-0.001). We further demonstrated that SMPD1 knockout and knockdown resulted in increased α-synuclein levels in HeLa and BE(2)-M17 dopaminergic cells and that the p.L302P and p.fsP330 mutations impair the traffic of acid-sphingomyelinase to the lysosome.

Conclusions: Our results support an association between SMPD1 variants, acid-sphingomyelinase activity, and PD. Furthermore, they suggest that reduced acid-sphingomyelinase activity may lead to α-synuclein accumulation. © 2019 International Parkinson and Movement Disorder Society.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469643PMC
http://dx.doi.org/10.1002/mds.27642DOI Listing

Publication Analysis

Top Keywords

acid-sphingomyelinase activity
20
ashkenazi jewish
16
smpd1 mutations
12
acid-sphingomyelinase
9
smpd1
8
α-synuclein accumulation
8
parkinson's disease
8
jewish cohort
8
10709 ashkenazi
8
jewish controls
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!